ADI invites Biogen to present aducanumab data

This 75-minute webinar will present the data for Biogen’s investigational drug aducanumab, which if approved, would be the first disease-modifying treatment for Alzheimer’s disease.

ADI is very pleased to invite Biogen to a webinar on the data from trials investigating the efficacy and safety of aducanumab, an investigational treatment for early Alzheimer’s disease.

Join us for this interesting webinar, which will see ADI’s Chief Executive Paola Barbarino, Chair of ADI’s Medical and Scientific Panel Dr. Alireza Atri, and Biogen’s Head of Neurodegeneration, Dr. Samantha Budd Haeberlein, present the data from Biogen’s Phase 3 clinical studies ENGAGE and EMERGE.

During the 75-minute session, Dr. Budd Haeberlein will present and explain the clinical trial data for Biogen’s investigational drug aducanumab which is currently under regulatory review. If approved, aducanumab would be the first disease-modifying treatment for Alzheimer’s disease. Paola and Dr. Atri will then moderate a question and answer session.

Register for the webinar

You will have the opportunity to submit any questions ahead of the session in the Zoom registration form under the heading ‘Questions & Comments’.